Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

This study has been completed.

Study NCT00388063 Information provided by Callisto Pharmaceuticals

First Received: October 11, 2006 Last Updated: December 17, 2007 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	September 2007
Estimated Primary Completion Date:	No date given